Advertisement

Topics

STAT Plus: Will tiny OncoSec break out with promising melanoma immunotherapy study results?

07:30 EST 8 Nov 2017 | STAT

Investors have largely ignored OncoSec’s approach to boosting patients' response rates to cancer immunotherapy, but that may change with new data Wednesday.

Original Article: STAT Plus: Will tiny OncoSec break out with promising melanoma immunotherapy study results?

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Will tiny OncoSec break out with promising melanoma immunotherapy study results?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...